Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
INCR · Nasdaq · United States · Pharmaceutical Preparations
In shortIntercure Ltd. is loss-making, burns cash and carries moderate debt, with revenue shrinking (−32.8% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -28.1% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -28.4% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -15.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -9.7% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.73× | 77/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.46× | 85/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.78 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -29.9% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 272.0% | 0/100 |
| Operating margin volatility | 30.3% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.8% | 32/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
ILS millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 65 | 220 | 389 | 356 | 239 |
| Cost of revenue | 35 | 124 | 230 | 247 | 203 |
| Gross profit | 32 | 91 | 155 | 105 | 30 |
| Research & development | 1.6 | 1.2 | 0.6 | 0.4 | 0.4 |
| Operating income | (38) | 28 | 51 | (42) | (67) |
| Pre-tax income | (38) | 19 | 44 | (61) | (87) |
| Income tax | (2.3) | 11 | 0.1 | 2.2 | (15) |
| Net income | (37) | 4.7 | 45 | (62) | (68) |
| Diluted EPS | −ILS1.42 | ILS0.11 | ILS0.99 | −ILS1.36 | −ILS1.48 |
| Diluted shares (millions) | 25 | 38 | 45 | 46 | 46 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
0.78 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
1/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated May 1, 2025